Live
FierceBiotechSanofi’s bispecific scores double respiratory phase 2 wins, but flunks eczema studyFierceBiotechBiogen links up with Alloy platform to boost ASO drug developmentEndpoints NewsBioNTech to shutter Singapore HQ after 'comprehensive review'Endpoints NewsSanofi bispecific sails through asthma, sinusitis trials, but disappoints in eczemaeLifeSeparating selection from mutation in antibody language modelseLifeRethinking how memories are retrievedThermo FisherHow Thermo Fisher’s Glacios 3 aims to broaden access to cryo-EM - R&D WorldThermo FisherLobbying Update: $21,000 of THERMO FISHER SCIENTIFIC INC lobbying was just disclosed - Quiver QuantitativeFierceBiotechTakeda tears up Denali partnership, returning dementia asset amid restructuringFierceBiotechAI model designs new treatment candidate for opioid addiction that cuts cravings in ratsAgilentAgilent CLO Departing With Severance After Less Than 2 Years in Role - Law.comBioPharma DiveHims & Hers says limited data stolen in social engineering attack
eLife Mar 13, 2026

Readout and delayed transmission of initial afferent V1 activity in decisions about stimulus contrast

Readout and delayed transmission of initial afferent V1 activity in decisions about stimulus contrast

Original
Body unavailable. Use the original source.

Directory

59 All